Replies to post #169477 on Biotech Values

[jq1234]

I just looked at Investor Day presentation. You can see Genentech was much more conservative in their approach to dosing, CRIS was pushing to higher BID continuous dosing regimen. Based on preclinical model, it really doesn't make any difference in efficacy between BID and QD at higher dose. I'd go with Genentech's dosing regimen.

The thing with toxicity is it doesn't have to show up to everyone at higher dose to be considered toxic. This happens in a very small population, it could happen much more frequently in larger population even if you narrows inclusion criteria.